April 14, 2025 4:42pm

The lingering question is, who is pulling at both ends?

The process is a game determined by who will be bested in the session

I say today what others won't, so you can do what others can't!

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets. I put hours of effort to create reporting, while leveraging my 40 years of operating and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

RegMed Investors’ (RMi) pre-open: trending challenge … https://www.regmedinvestors.com/articles/13878

Friday night’s RegMed Investors (RMi) Closing Bell: back on the green … https://www.regmedinvestors.com/articles/13877

 

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), formerly Biostage (OTCQB: HRGN) The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812

 

Monday: The Dow closed UP +312.08 points or +0.78%, the S&P closed UP +42.61 points or +0.79% while the Nasdaq close UP +107.03 points or +0.64%

  • U.S. stocks bounced

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • Investors cheered Trump’s exemption of smartphones and computers, as well as other devices and components like semiconductors, from “reciprocal” tariffs,

Monday’s advance/decline line opened with a positive 21 incliner, 11 decliners and 3 flats ending with a positive close of 23 incliners, 7 decliners and 5 flats         

Metrics:  Monday, the IBB was up +3.34%, the XBI was up +2.22% while the VIX was down -6.64 points or -17.68% at 30.92

 

Q2/24 -April – 4 positive and 6 negative closes

  • Q1/25 – March, 10 positive and 12 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Monday’s Closing UP (10 of 23)

  • Lenz Therapeutics (LENZ +$2.98 after Friday’s +$1.72),
  • Alnylam Pharmaceuticals (ALNY +$2.24 after Friday’s +$11.49),
  • Blueprint Medicine (BPMC +$1.69 after Friday’s +$0.57),
  • Beam Therapeutics (BEAM +$1.53 after Friday’s +$0.84)
  • Verve Therapeutics (VERV +$0.86),
  • Ionis Pharmaceuticals (IONS +$0.78 after Friday’s +$1.19),
  • Ultragenyx Pharmaceuticals (RARE +$0.78 after Friday’s +$0.98),
  • Mesoblast (MESO +$0.60 after Friday’s -$0.26),
  • Moderna (MRNA +$0.60 after Friday’s +$1.70)
  • Regenxbio (RGNX +$0.44),

Flat (5)

  • Adverum Biotechnologies (ADVM)
  • Harvard Apparatus RT (OTCQB: HRGN $0.00)
  • Homology Medicine (FIXX)
  • Prime Medicine (PRME)
  • Precigen (PGEN)

Monday’s Closing DOWN (7 of 7):

  • CRISPR Therapeutics (CRSP -$0.49 after Friday’s +$5.04),
  • bluebird bio (BLUE -$0.39),
  • Fate Therapeutics (FATE -$),
  • Caribou Biosciences (CRBU -$0.1357),
  • MiMedx (MDXG -$0.0751 after Friday’s -$0.02),
  • Vericel (VCEL -$0.02 after Friday’s -$0.65),
  • Generation Bio (GBIO -$0.0133),

 

As compared to … Friday: The Dow closed UP +619.05 points or +1.56%, the S&P closed UP +95.31 points or +1.81% while the Nasdaq close UP +337.14 points or +2.06%

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • The University of Michigan consumer survey’s mid-month reading on sentiment fell to 50.8, down from 57.0 in March and below the consensus estimate for 54.6. Respondents’ expectation for inflation a year from now leaped to 6.7%, the highest level since November 1981 and up from 5% in March.
  • The move represented a 10.9% monthly change and was 34.2% lower than a year ago. It was lowest reading since June 2022 and the 2nd-lowest in the survey’s history going back to 1952.

Friday’s advance/decline line opened with a negative 13 incliner, 30 decliners and 2 flats ending with a positive close of 28 incliners, 5 decline and 2 flats            

Metrics:  Friday, the IBB was up +3.82%, the XBI was up +2.72% while the VIX was down -3.16 points or -7.76% at 37.56

 

 

The BOTTOM LINE:  A positive enhancer for the market… president Trump exempted electronics from new tariff regime.

  • Tariffs plunged financial markets battering stocks following of Trump's April announcements; the weekends and Monday’s news cooled market depressions.
  • And … have left investors and economists scrambling to nail down the precise impacts of this overhaul of America's trade relationships.

I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader - me” – they were pretty simple instructions to follow!

Reiterating … My message, “The Trump administration … realizes drugs need to be made in America, not in foreign companies to be imported.

  • Also, most drug research is American based and if Kennedy slows or impedes their development or more – he will be bounced faster than a bond sell-off!!
  • Mark my words …!!

My perspective is to continue to nibble on sector equities, NO all ins – just add those with solid partners, lengthened runways and solid cash positions leveraged by solid management teams – there I see losses going forward!

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

 

I don’t have much to write/say other than “electronic trading and uncle algo” slips in and out, back doors reaping sector disharmony and then pops right back for some profiteering.

  • What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.” <me>

 

April ‘25: understand the “flow” …

  • 4/14 - Monday closed positive with 23 positive, 7 negative and 5 flats
  • 4/11 – Friday closed positive with 28 positive, 5 negative and 2 flats
  • 4/10 – Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 4/9 – Wednesday closed positive with 33 positive, 1 negative and 1 flat
  • 4/8 - Tuesday closed negative with 4 positive, 30 negative and 1 flat
  • 4/7 - Monday closed negative with 13 positive, 20 negative and 2 flats
  • 4/4 – Friday closed negative with 3 positive, 30 negative and 2 flats
  • 4/3 – Thursday closed negative with 2 positive, 32 negative and 1 flat
  • 4/2 - Wednesday closed positive with 9 positive, 25 negative and 1 flat
  • 4/1 - Tuesday closed negative with 5 positive, 28 negative and 2 flats

 

What could 2025 have in store for the capital access space?

  • "You'll see a number of cell and gene therapy companies DESPARITE drive for financings – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in pipelines … capital expansion is second.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Monday: Lenz Therapeutics (LENZ), Alnylam Pharmaceuticals (ALNY) and Blueprint Medicine (BPMC)
  • Friday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Lenz Therapeutics (LENZ)

The worst three (3) in the session: 

  • Monday: and Blueprint Medicine (BPMC), bluebird bio (BLUE) and Fate Therapeutics (FATE)
  • Friday: Vericel (VCEL), Mesoblast (MESO) and Brainstorm Cell Therapeutics (BCLI)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.